Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Retinoic acid receptors and Retinoid X Receptors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Retinoic acid receptors and Retinoid X Receptors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Retinoic acid receptors (RAR) and Retinoid X Receptors (RXR) are nuclear receptors that are targets for various kinds of diseases. RAR is activated by all-trans-retinoic acid and 9-cis retinoic acid. RAR are ligand-controlled transcription factors that function as heterodimers with RXRs and regulate cell growth, cell differentiation, cell survival, and cell death. RAR has three subtypes – α,β, and γ that form heterodimer complexes with RXR to orchestrate complex events such as organ homeostasis, reproduction, and immune function. Without a ligand, the RAR/RXR dimer binds to hormone response elements known as retinoic acid response elements (RAREs) that form complexes with corepressor proteins. Binding of an agonist ligand to the RAR results in corepressor dissociation and coactivator protein recruitment, facilitating the transcription of downstream target genes into mRNA and, ultimately, protein. The success of retinoic acid-based therapy in the treatment of acute promyelocytic leukemia (APL) and the improved understanding of the biological roles of RAR and RXR have led to the development of RAR and RXR modulators for cancer therapy. Bexarotene selectively binds to and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ). RXR can form heterodimers with various receptor partners, including retinoic acid receptor (RAR), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptor (PPAR). RAR/RXR has been associated with regulating inflammation and the immune system, maintaining synaptic plasticity and axonal regeneration. These drugs have been used to treat many diseases, such as Acne Vulgaris, Cutaneous T cell Lymphoma, Atopic Dermatitis, Psoriasis, Papulosquamous skin disease, and many others. Extensive research is being conducted globally to discover new and novel molecules for RAR/RXR, like tretinoin used for treating Acne Vulgaris. The development and launch of new products will thus increase the market's revenue in the forecasted years. Many of these drugs are on the market, while many are in ongoing clinical trials. Many companies have various products in their pipelines, with 45 products in different stages of clinical trials. 8 products in Phase 4, 10 in Phase 3, 8 in Phase 2, and 1 in Phase 1 of the clinical trials.
Key Developments of RAR/RXR
Approved molecules of RAR/RXR
Drugs in the Pipeline of RAR/RXR
Clinical Activity and Developments of RAR/RXR
As of July 2023, 45 companies have many products for 358 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Targretin oral (bexarotene oral) |
45 |
|
Toctino (alitretinoin) |
21 |
|
Duobrii (halobetasol/tazarotene) |
17 |
|
Aklief (trifarotene) |
15 |
|
isotretinoin |
10 |
Drugs like Targretin oral (bexarotene oral) and Toctino (alitretinoin) have been approved by the FDA and other regulatory agencies for treating various diseases, with the treatment of Acne Vulgaris being the major indication. Targretin oral acts by binding and activating retinoid x receptor subtypes and is indicated for treating cutaneous manifestations of Cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Toctino is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma, Chronic hand eczema, and psoriasis. These drugs have also been approved for indications like Atopic Dermatitis and Hypersensitivity reactions. These are also being tested in various clinical trials for indications like Sarcomas, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus, and many others.
According to the Asthma and Allergy Foundation of America, in 2021, about 25 million people suffered from Allergy related diseases (about 1 in every 13 Americans). About 5 million American children have asthma, according to the same report. According to the National Eczema Association, approximately 31.6 million people in the United States will have some form of eczema in 2022, with prevalence peaking in early childhood. It is estimated that 13% of Native Americans and Asian or Pacific Islanders, and 11% of Caucasians in the United States suffer from eczema. Approximately 9.6 million children under 18 in the United States have atopic dermatitis (AD), and an estimated 16.5 million adults have AD, 80% of whom had atopic dermatitis before the age of 6 years. Suffer from According to the report, more than 55% of adults with moderate to severe Alzheimer's disease reported poorly controlled disease. In Europe, more than 8% of adults and 8.4% to 18.6% of adolescents by the age of 18 are expected to have Alzheimer's disease by 2023, according to research reports.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Targretin oral (bexarotene oral), Toctino (alitretinoin), Duobrii (halobetasol/tazarotene) and Aklief (trifarotene) are some of the drugs approved by various regulatory agencies.
The two approved drugs are used in adults for indications like Acne Vulgaris, Cutaneous T-cell lymphoma, AIDS related Kaposi’s sarcoma, Sarcomas, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus, and many others.
Roche, Basilea Pharmaceuticals, GSK, Galderma and Syros Pharmaceuticals are some of the major market players for RAR/RXR.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and rising incidence of Acne Vulgaris, Cutaneous T-cell lymphoma, Systemic Lupus Erythematosus, and others are the key opportunities for RAR/RXR in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.